The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
See Gordon and Tijms (doi:10.1093/brain/awz278) for a scientific commentary on this article. Jack et al. examine relationships between the bivariate distribution of β-amyloid and tau on PET and established neurocognitive clinical syndromes. Amyloidosis appears to be required for high levels of 3R/4R tau deposition. Whereas abnormal amyloid PET is compatible with normal cognition, highly abnormal tau PET is not.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tau PET uptake occurs at a later stage and age than amyloid Pet and is more closely associated with cognitive dysfunction than amyloid-PET.(442, 443)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [443]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“robust evidence indicates that cerebral Aβ accumulation is one of the earliest mechanistic alterations of the whole pathophysiological dynamic of AD (104–107).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, CSF and positron emission tomography longitudinal studies support the hypothetical pathophysiological model of AD for which amyloidosis proceeds, either promoting or being permissive to the spreading of tau pathology that is likely to drive disease clinical evolution (104–107).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several genetic data studies (306 autosomal dominant mutations plus the APP gene duplication and trisomy 21) and multimodal biomarker studies indicate that an imbalance between Aβ production and clearance plays a critical and early role in AD pathogenesis (104–106,113,114).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredIn the citing paper
“A large amount of evidence also supports the hypothesis that cerebral Aβ deposition begins decades before AD clinical onset and prior to cortical spreading of tau pathology.”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Self-citationSensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476 · cited 12×
“Probable DLB participants were distributed between the A T and A + T quadrants (Fig.”
InfluentialSelf-citationJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Self-citationClinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 1×
“Our data along with that from other studies (Arriagada et al., 1992; Ingelsson et al., 2004; Bateman et al., 2012; Benzinger et al., 2013; Xiong et al., 2016; Leal et al., 2018; Hanseeuw et al., 2019) support a dynamic biomarker model (Jack et al.”
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · cited 1×
“, 2014), a neuropathological entity attributed to ageing that is distinct from Alzheimer’s disease (Hyman et al., 2012).”
mclust 5: Clustering, Classification and Density Estimation Using Gaussian Finite Mixture Models
Scrucca, L., Fop, M., Murphy, T., & Raftery, A. (2016) · The R Journal · doi:10.32614/rj-2016-021 · Cited by 2,892
Appelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,760
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Model-Based Gaussian and Non-Gaussian Clustering
Banfield, J. D., & Raftery, A. E. (1993) · Biometrics · doi:10.2307/2532201 · Cited by 2,395
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“An important caveat to the conclusion above is that autopsy data show that medial temporal tauopathy likely precedes neocortical amyloidosis in most people (Braak et al., 2011).”
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“This suggests that high levels of amyloid are compatible with unimpaired cognitive status while high levels of tau are not, a finding that is consistent with prior evidence that cognitive impairment in Alzheimer’s disease is more closely linked to tau than amyloid-b (Arriagada et al., 1992; Gomez-Isla et al., 1997; Be…”
Qualitative Assessment of Verbal Fluency Performance in Frontotemporal Dementia
van den Berg, E., Jiskoot, L. C., Grosveld, M. J. H., van Swieten, J. C., & Papma, J. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477538 · Cited by 2,046
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., et al. (2019) · Brain · doi:10.1093/brain/awz099 · Cited by 1,547
Self-citationNeuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489 · cited 1×
“This suggests that high levels of amyloid are compatible with unimpaired cognitive status while high levels of tau are not, a finding that is consistent with prior evidence that cognitive impairment in Alzheimer’s disease is more closely linked to tau than amyloid-b (Arriagada et al., 1992; Gomez-Isla et al., 1997; Be…”
Self-citationPrimary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467 · cited 1×
“Medial/basal temporal lobe tauopathy with no or minimal amyloidosis has been labelled primary agerelated tauopathy (Crary et al., 2014), a neuropathological entity attributed to ageing that is distinct from Alzheimer’s disease (Hyman et al.”
Self-citationThe Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
PET Imaging of Tau Deposition in the Aging Human Brain
Schöll, M., Lockhart, S. N., Schonhaut, D. R., O’Neil, J. P., Janabi, M., Ossenkoppele, R., Baker, S. L., Vogel, J. W., Faria, J., Schwimmer, H. D., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.028 · Cited by 1,214
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“indicator of underlying aetiology (Beach et al., 2012; Jagust et al., 2019).”
Tau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986
Defining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931
Self-citationAssociation of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study
Hanseeuw, B. J., Betensky, R. A., Jacobs, H. I. L., Schultz, A. P., Sepulcre, J., Becker, J. A., Cosio, D. M. O., Farrell, M., Quiroz, Y. T., Mormino, E. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1424 · Cited by 865
Roberts, R. O., Geda, Y. E., Knopman, D. S., Cha, R. H., Pankratz, V. S., Boeve, B. F., Ivnik, R. J., Tangalos, E. G., Petersen, R. C., & Rocca, W. A. (2008) · Neuroepidemiology · doi:10.1159/000115751 · Cited by 793
Self-citationPrevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-analysis
Ossenkoppele, R., Jansen, W. J., Rabinovici, G. D., Knol, D. L., van der Flier, W. M., van Berckel, B. N. M., Scheltens, P., Visser, P. J., Verfaillie, S. C. J., Zwan, M. D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4669 · Cited by 677
Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808
Chien, D. T., Szardenings, A. K., Bahri, S., Walsh, J. C., Mu, F., Xia, C., Shankle, W. R., Lerner, A. J., Su, M.-Y., Elizarov, A., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130098 · Cited by 675
Rabinovici, G. D., Gatsonis, C., Apgar, C., Chaudhary, K., Gareen, I., Hanna, L., Hendrix, J., Hillner, B. E., Olson, C., Lesman-Segev, O. H., et al. (2019) · JAMA · doi:10.1001/jama.2019.2000 · Cited by 674
Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
Ingelsson, M., Fukumoto, H., Newell, K. L., Growdon, J. H., Hedley–Whyte, E. T., Frosch, M. P., Albert, M. S., Hyman, B. T., & Irizarry, M. C. (2004) · Neurology · doi:10.1212/01.wnl.0000115115.98960.37 · Cited by 666
St. Sauver, J. L., Grossardt, B. R., Leibson, C. L., Yawn, B. P., Melton, L. J., & Rocca, W. A. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.11.009 · Cited by 651
Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651 · cited 3×
“Flortaucipir was developed to bind to the 3R/4R form of pathological tau that characterizes Alzheimer’s disease (Chien et al., 2013; Lowe et al., 2016; Lemoine et al., 2017; Marquie et al., 2017).”
Gordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30028-0 · Cited by 602
Self-citationIrwin, D. J., Grossman, M., Weintraub, D., Hurtig, H. I., Duda, J. E., Xie, S. X., Lee, E. B., Van Deerlin, V. M., Lopez, O. L., Kofler, J. K., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30291-5 · Cited by 588
Bennett, D. A., Schneider, J. A., Wilson, R. S., Bienias, J. L., & Arnold, S. E. (2004) · Archives of Neurology · doi:10.1001/archneur.61.3.378 · Cited by 526 · cited 1×
“This suggests that high levels of amyloid are compatible with unimpaired cognitive status while high levels of tau are not, a finding that is consistent with prior evidence that cognitive impairment in Alzheimer’s disease is more closely linked to tau than amyloid-b (Arriagada et al., 1992; Gomez-Isla et al., 1997; Be…”
In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum
Cho, H., Choi, J. Y., Hwang, M. S., Kim, Y. J., Lee, H. M., Lee, H. S., Lee, J. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2016) · Annals of Neurology · doi:10.1002/ana.24711 · Cited by 499
Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia
Rabinovici, G. D., Jagust, W. J., Furst, A. J., Ogar, J. M., Racine, C. A., Mormino, E. C., O'Neil, J. P., Lal, R. A., Dronkers, N. F., Miller, B. L., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21451 · Cited by 477 · cited 1×
“…a half investigators in the ageing and dementia field have thoroughly examined relationships between amyloid PET and various clinical presentations (Rabinovici et al., 2008; Nordberg et al., 2013; Villemagne et al., 2013; Ossenkoppele et al., 2015; Bilgel et al., 2018; Buckley et al., 2018; Gordon…”
BackgroundAn autoradiographic evaluation of AV-1451 Tau PET in dementia
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474
Self-citationOssenkoppele, R., Rabinovici, G. D., Smith, R., Cho, H., Schöll, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., et al. (2018) · JAMA · doi:10.1001/jama.2018.12917 · Cited by 472
Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease
Maass, A., Landau, S., Baker, S. L., Horng, A., Lockhart, S. N., La Joie, R., Rabinovici, G. D., & Jagust, W. J. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.05.058 · Cited by 462 · cited 2×
“Questions about which areas of the brain should be measured and what constitute valid or useful cut points are still under investigation (Cho et al., 2016a; Johnson et al., 2016; Scholl et al., 2016; Villemagne et al., 2016; Maass et al., 2017; Mishra et al., 2017; Pontecorvo et al., 2017a; Lowe et al., 2018).”
Neuropathologic Substrate of Mild Cognitive Impairment
Markesbery, W. R., Schmitt, F. A., Kryscio, R. J., Davis, D. G., Smith, C. D., & Wekstein, D. R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.38 · Cited by 460 · cited 1×
“This reflects the aetiological heterogeneity of the MCI syndrome (Markesbery et al., 2006).”
Pathological correlates of dementia in a longitudinal, population‐based sample of aging
Sonnen, J. A., Larson, E. B., Crane, P. K., Haneuse, S., Li, G., Schellenberg, G. D., Craft, S., Leverenz, J. B., & Montine, T. J. (2007) · Annals of Neurology · doi:10.1002/ana.21208 · Cited by 432
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease
Benzinger, T. L. S., Blazey, T., Jack, C. R., Koeppe, R. A., Su, Y., Xiong, C., Raichle, M. E., Snyder, A. Z., Ances, B. M., Bateman, R. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317918110 · Cited by 391 · cited 1×
“Our data along with that from other studies (Arriagada et al., 1992; Ingelsson et al., 2004; Bateman et al., 2012; Benzinger et al., 2013; Xiong et al., 2016; Leal et al., 2018; Hanseeuw et al., 2019) support a dynamic biomarker model (Jack et al.”
Self-citationNelson, P. T., Head, E., Schmitt, F. A., Davis, P. R., Neltner, J. H., Jicha, G. A., Abner, E. L., Smith, C. D., Van Eldik, L. J., Kryscio, R. J., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0826-y · Cited by 365
Pontecorvo, M. J., Devous, M. D., Navitsky, M., Lu, M., Salloway, S., Schaerf, F. W., Jennings, D., Arora, A. K., McGeehan, A., Lim, N. C., et al. (2017) · Brain · doi:10.1093/brain/aww334 · Cited by 357
Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., et al. (2015) · Brain · doi:10.1093/brain/awv050 · Cited by 324 · cited 1×
“Third, cut points for amyloid PET have been validated against neuropathology (Murray et al., 2015; La Joie et al., 2019).”
Self-citationLa Joie, R., Ayakta, N., Seeley, W. W., Borys, E., Boxer, A. L., DeCarli, C., Doré, V., Grinberg, L. T., Huang, E., Hwang, J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.001 · Cited by 317 · cited 1×
“Third, cut points for amyloid PET have been validated against neuropathology (Murray et al., 2015; La Joie et al., 2019).”
BackgroundSelf-citationMultiple pathologies are common and related to dementia in the oldest-old: The 90+ Study
Kawas, C. H., Kim, R. C., Sonnen, J. A., Bullain, S. S., Trieu, T., & Corrada, M. M. (2015) · Neurology · doi:10.1212/wnl.0000000000001831 · Cited by 303 · cited 3×
“…pathologies, for which no biomarkers presently exist, are highly prevalent in older individuals (most often co-morbidly), and exert significant effects on cognition (Schneider et al., 2007; Sonnen et al., 2007; Nelson et al., 2011; Kawas et al., 2015; Botha et al., 2018a, b; Petersen, 2018).”
Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia
Lowe, V. J., Wiste, H. J., Senjem, M. L., Weigand, S. D., Therneau, T. M., Boeve, B. F., Josephs, K. A., Fang, P., Pandey, M. K., Murray, M. E., et al. (2018) · Brain · doi:10.1093/brain/awx320 · Cited by 302
Self-citationEntorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging
Maass, A., Lockhart, S. N., Harrison, T. M., Bell, R. K., Mellinger, T., Swinnerton, K., Baker, S. L., Rabinovici, G. D., & Jagust, W. J. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.2028-17.2017 · Cited by 286
The impact of amyloid‐beta and tau on prospective cognitive decline in older individuals
Sperling, R. A., Mormino, E. C., Schultz, A. P., Betensky, R. A., Papp, K. V., Amariglio, R. E., Hanseeuw, B. J., Buckley, R., Chhatwal, J., Hedden, T., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25395 · Cited by 286
Buckley, R. F., Mormino, E. C., Amariglio, R. E., Properzi, M. J., Rabin, J. S., Lim, Y. Y., Papp, K. V., Jacobs, H. I. L., Burnham, S., Hanseeuw, B. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.04.010 · Cited by 276 · cited 1×
“…various clinical presentations (Rabinovici et al., 2008; Nordberg et al., 2013; Villemagne et al., 2013; Ossenkoppele et al., 2015; Bilgel et al., 2018; Buckley et al., 2018; Gordon et al., 2018; Jansen et al., 2018; Lim et al., 2018; Lopez et al., 2018; Leuzy et al., 2019; Timmers et al., 2019).”
Tau PET in Alzheimer disease and mild cognitive impairment
Cho, H., Choi, J. Y., Hwang, M. S., Lee, J. H., Kim, Y. J., Lee, H. M., Lyoo, C. H., Ryu, Y. H., & Lee, M. S. (2016) · Neurology · doi:10.1212/wnl.0000000000002892 · Cited by 270
Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum
Jones, D. T., Graff-Radford, J., Lowe, V. J., Wiste, H. J., Gunter, J. L., Senjem, M. L., Botha, H., Kantarci, K., Boeve, B. F., Knopman, D. S., et al. (2017) · Cortex · doi:10.1016/j.cortex.2017.09.018 · Cited by 236
Self-citationTau Positron Emission Tomographic Imaging in the Lewy Body Diseases
Gomperts, S. N., Locascio, J. J., Makaretz, S. J., Schultz, A., Caso, C., Vasdev, N., Sperling, R., Growdon, J. H., Dickerson, B. C., & Johnson, K. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3338 · Cited by 227
Walker, L., McAleese, K. E., Thomas, A. J., Johnson, M., Martin-Ruiz, C., Parker, C., Colloby, S. J., Jellinger, K., & Attems, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1406-3 · Cited by 225
A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease
Nordberg, A., Carter, S. F., Rinne, J., Drzezga, A., Brooks, D. J., Vandenberghe, R., Perani, D., Forsberg, A., Långström, B., Scheinin, N., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2237-2 · Cited by 186
AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies
Kantarci, K., Lowe, V. J., Boeve, B. F., Senjem, M. L., Tosakulwong, N., Lesnick, T. G., Spychalla, A. J., Gunter, J. L., Fields, J. A., Graff‐Radford, J., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24825 · Cited by 181
Self-citationGordon, B. A., Blazey, T. M., Christensen, J., Dincer, A., Flores, S., Keefe, S., Chen, C., Su, Y., McDade, E. M., Wang, G., et al. (2019) · Brain · doi:10.1093/brain/awz019 · Cited by 180
Self-citationAV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure
Mishra, S., Gordon, B. A., Su, Y., Christensen, J., Friedrichsen, K., Jackson, K., Hornbeck, R., Balota, D. A., Cairns, N. J., Morris, J. C., et al. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.07.050 · Cited by 175
de Wilde, A., van der Flier, W. M., Pelkmans, W., Bouwman, F., Verwer, J., Groot, C., van Buchem, M. M., Zwan, M., Ossenkoppele, R., Yaqub, M., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1346 · Cited by 152
Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders
Coughlin, D., Xie, S. X., Liang, M., Williams, A., Peterson, C., Weintraub, D., McMillan, C. T., Wolk, D. A., Akhtar, R. S., Hurtig, H. I., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25392 · Cited by 146
Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia
Jansen, W. J., Ossenkoppele, R., Tijms, B. M., Fagan, A. M., Hansson, O., Klunk, W. E., van der Flier, W. M., Villemagne, V. L., Frisoni, G. B., Fleisher, A. S., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3391 · Cited by 140
Subthreshold Amyloid Predicts Tau Deposition in Aging
Leal, S. L., Lockhart, S. N., Maass, A., Bell, R. K., & Jagust, W. J. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.0485-18.2018 · Cited by 133
Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI
Landau, S. M., Horng, A., Fero, A., Jagust, W. J., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., Weiner, M., Aisen, P., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002576 · Cited by 127
Self-citationFDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis
Botha, H., Mantyh, W. G., Murray, M. E., Knopman, D. S., Przybelski, S. A., Wiste, H. J., Graff-Radford, J., Josephs, K. A., Schwarz, C. G., Kremers, W. K., et al. (2018) · Brain · doi:10.1093/brain/awy049 · Cited by 115
Self-citation[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging
Marquié, M., Siao Tick Chong, M., Antón-Fernández, A., Verwer, E. E., Sáez-Calveras, N., Meltzer, A. C., Ramanan, P., Amaral, A. C., Gonzalez, J., Normandin, M. D., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1740-8 · Cited by 109
Chiotis, K., Saint-Aubert, L., Rodriguez-Vieitez, E., Leuzy, A., Almkvist, O., Savitcheva, I., Jonasson, M., Lubberink, M., Wall, A., Antoni, G., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.108 · Cited by 108
Lemoine, L., Gillberg, P.-G., Svedberg, M., Stepanov, V., Jia, Z., Huang, J., Nag, S., Tian, H., Ghetti, B., Okamura, N., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0325-z · Cited by 107
Forsberg, A., Almkvist, O., Engler, H., Wall, A., Langstrom, B., & Nordberg, A. (2010) · Current Alzheimer Research · doi:10.2174/156720510790274446 · Cited by 105
Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects
Knopman, D. S., Lundt, E. S., Therneau, T. M., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., Machulda, M. M., et al. (2019) · Brain · doi:10.1093/brain/awz025 · Cited by 97
Self-citationEffects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults
Bilgel, M., An, Y., Helphrey, J., Elkins, W., Gomez, G., Wong, D. F., Davatzikos, C., Ferrucci, L., & Resnick, S. M. (2018) · Brain · doi:10.1093/brain/awy150 · Cited by 94
How early can we diagnose Alzheimer disease (and is it sufficient)?: The 2017 Wartenberg lecture
Petersen, R. C. (2018) · Neurology · doi:10.1212/wnl.0000000000006088 · Cited by 89
Self-citationA Comparison of Partial Volume Correction Techniques for Measuring Change in Serial Amyloid PET SUVR
Schwarz, C. G., Gunter, J. L., Lowe, V. J., Weigand, S., Vemuri, P., Senjem, M. L., Petersen, R. C., Knopman, D. S., & Jack, C. R. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180749 · Cited by 85
Self-citationLim, Y. Y., Kalinowski, P., Pietrzak, R. H., Laws, S. M., Burnham, S. C., Ames, D., Villemagne, V. L., Fowler, C. J., Rainey-Smith, S. R., Martins, R. N., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4325 · Cited by 84
Suspected non-AD pathology in mild cognitive impairment
Wisse, L. E. M., Butala, N., Das, S. R., Davatzikos, C., Dickerson, B. C., Vaishnavi, S. N., Yushkevich, P. A., & Wolk, D. A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.029 · Cited by 78
Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality
López, O. L., Becker, J. T., Chang, Y., Klunk, W. E., Mathis, C. A., Price, J., Aizenstein, H. J., Snitz, B. E., Cohen, A. D., DeKosky, S. T., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005549 · Cited by 64
Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project
Timmers, T., Ossenkoppele, R., Verfaillie, S. C. J., van der Weijden, C. W. J., Slot, R. E. R., Wesselman, L. M. P., Windhorst, A. D., Wolters, E. E., Yaqub, M., Prins, N. D., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.02.020 · Cited by 63 · cited 1×
“, 2004), and over the past decade and a half investigators in the ageing and dementia field have thoroughly examined relationships between amyloid PET and various clinical presentations (Rabinovici et al., 2008; Nordberg et al., 2013; Villemagne et al., 2013; Ossenkoppele et al., 2015; Bilgel et al., 2018; Buckley et…”
Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis
Leuzy, A., Savitcheva, I., Chiotis, K., Lilja, J., Andersen, P., Bogdanovic, N., Jelic, V., & Nordberg, A. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04297-5 · Cited by 60
Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study
Xiong, C., Jasielec, M. S., Weng, H., Fagan, A. M., Benzinger, T. L. S., Head, D., Hassenstab, J., Grant, E., Sutphen, C. L., Buckles, V., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002593 · Cited by 54 · cited 1×
“Our data along with that from other studies (Arriagada et al., 1992; Ingelsson et al., 2004; Bateman et al., 2012; Benzinger et al., 2013; Xiong et al., 2016; Leal et al., 2018; Hanseeuw et al., 2019) support a dynamic biomarker model (Jack et al.”
Amyloid imaging in dementias with atypical presentation
Wolk, D. A., Price, J. C., Madeira, C., Saxton, J. A., Snitz, B. E., Lopez, O. L., Mathis, C. A., Klunk, W. E., & DeKosky, S. T. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.07.003 · Cited by 49
Effectiveness of Florbetapir PET Imaging in Changing Patient Management
Pontecorvo, M. J., Siderowf, A., Dubois, B., Doraiswamy, P. M., Frisoni, G. B., Grundman, M., Nobili, F., Sadowsky, C. H., Salloway, S., Arora, A. K., et al. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000478007 · Cited by 46
“Alzheimer's disease” is neither “Alzheimer's clinical syndrome” nor “dementia”
Jagust, W. J., Jack, C. R., Bennett, D. A., Blennow, K., Haeberlein, S. B., Holtzman, D. M., Jessen, F., Karlawish, J. H., Liu, E., Molinuevo, J. L., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.11.002 · Cited by 43
Self-citationTau-negative amnestic dementia masquerading as Alzheimer disease dementia
Botha, H., Mantyh, W. G., Graff-Radford, J., Machulda, M. M., Przybelski, S. A., Wiste, H. J., Senjem, M. L., Parisi, J. E., Petersen, R. C., Murray, M. E., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005124 · Cited by 39
Self-citationVillemagne, V. L., Doré, V., Bourgeat, P., Cummins, T. L., Pejoska, S., Mulligan, R. S., Margison, L., Williams, R. C., Salvado, O., Masters, C. L., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.437 · Cited by 4
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationKnopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Self-citationThe Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
“In the clinical setting, neuroimaging of sporadic Alzheimer’s patients show the increased cortical tau-PET ligand retention only in the presence of Aβ accumulation, which is also associated with cortical atrophy in AD.(110) In addition, longitudinal studies idenfied that antecedent Aβ aggregates could successfully pre…”
Background
Metadata
- Authors
- Jack, C. R., Wiste, H. J., Botha, H., Weigand, S. D., Therneau, T. M., Knopman, D. S., Graff-Radford, J., Jones, D. T., Ferman, T. J., Boeve, B. F., Kantarci, K., Lowe, V. J., Vemuri, P., Mielke, M. M., Fields, J. A., Machulda, M. M., Schwarz, C. G., Senjem, M. L., Gunter, J. L., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- Department of Neurology, Mayo Clinic, Rochester, MN, USA
- Corresponding author
- Jack, Clifford R
- ORCID
- Jack, Clifford R
- Wiste, Heather J
- Botha, Hugo
- Weigand, Stephen D
- Therneau, Terry M
- Knopman, David S
- Jones, David T
- Ferman, Tanis J
- Boeve, Bradley F
- Kantarci, Kejal
- Lowe, Val J
- Vemuri, Prashanthi
- Mielke, Michelle M
- Fields, Julie A
- Machulda, Mary M
- Schwarz, Christopher G
- Senjem, Matthew L
- Gunter, Jeffrey L
- Petersen, Ronald C
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-09-09
- Volume
- 142
- Issue
- 10
- Pages
- 3230-3242
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC6763736
- OpenAlex
- W2972315303
- Cited by
- 200
- References
- 93
- Citations by year
- 2026: 15 · 2025: 23 · 2024: 31 · 2023: 34 · 2022: 32 · 2021: 31 · 2020: 31 · 2019: 3
- FWCI
- 19.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (R37 AG011378, RO1 AG041851, R01 AG056366, R01 NS097495, U01 AG06786, R01 AG034676, P50 AG016574)
- GHR Foundation
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- tau PET, amyloid-beta, bivariate distributions, mild cognitive impairment, frontotemporal dementia, dementia with Lewy bodies, Alzheimer's disease, tauopathy, amyloidosis, standardized uptake value ratio, cognitive aging, neurodegeneration biomarkers, Mayo Clinic Study of Aging, clinical syndromes
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alzheimer Disease, Amyloid, Amyloidosis, Brain, Cognition, Female, Humans, Longitudinal Studies, Male, Middle Aged, Neuropsychological Tests, Biomarkers, Amyloid beta-Peptides, tau Proteins, Neurocognitive Disorders, Tauopathies, Positron-Emission Tomography, Frontotemporal Dementia, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.